Nofar Torika1, Keren Asraf1, Ron N Apte2, Sigal Fleisher-Berkovich1. 1. Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beersheba, Israel. 2. Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beersheba, Israel.
Abstract
AIMS: Alzheimer's disease (AD) pathology is associated with brain inflammation involving microglia and astrocytes. The renin-angiotensin system contributes to brain inflammation associated with AD pathology. This study aimed to investigate the role of candesartan, an angiotensin II type 1 receptor blocker, in modulation of glial functions associated with AD. METHODS: Focusing on the role of candesartan in glial inflammation, we evaluated inflammatory mediators' levels, secreted by lipopolysaccharide-induced microglia following candesartan treatment. Also, short-term intranasal candesartan effects on amyloid burden and microglial activation were investigated in 5 familial AD mice. RESULTS: Candesartan showed anti-inflammatory effects and shifted microglial activation toward a more neuroprotective phenotype. Candesartan decreased the lipopolysaccharide-induced nitric oxide synthase and cyclooxygenase-2 expression levels, which was accompanied by an induction of arginase-1 expression levels and enhanced Aβ1-42 uptake by microglia. Moreover, intranasally administered candesartan to AD mice model significantly reduced the amyloid burden and microglia activation in the hippocampus. CONCLUSIONS: These results thus shed light on the neuroprotective role of candesartan in the early stage of AD, which might relate to modulation of microglial activation states.
AIMS: Alzheimer's disease (AD) pathology is associated with brain inflammation involving microglia and astrocytes. The renin-angiotensin system contributes to brain inflammation associated with AD pathology. This study aimed to investigate the role of candesartan, an angiotensin II type 1 receptor blocker, in modulation of glial functions associated with AD. METHODS: Focusing on the role of candesartan in glial inflammation, we evaluated inflammatory mediators' levels, secreted by lipopolysaccharide-induced microglia following candesartan treatment. Also, short-term intranasal candesartan effects on amyloid burden and microglial activation were investigated in 5 familial ADmice. RESULTS:Candesartan showed anti-inflammatory effects and shifted microglial activation toward a more neuroprotective phenotype. Candesartan decreased the lipopolysaccharide-induced nitric oxide synthase and cyclooxygenase-2 expression levels, which was accompanied by an induction of arginase-1 expression levels and enhanced Aβ1-42 uptake by microglia. Moreover, intranasally administered candesartan to ADmice model significantly reduced the amyloid burden and microglia activation in the hippocampus. CONCLUSIONS: These results thus shed light on the neuroprotective role of candesartan in the early stage of AD, which might relate to modulation of microglial activation states.
Authors: M J McKinley; A L Albiston; A M Allen; M L Mathai; C N May; R M McAllen; B J Oldfield; F A O Mendelsohn; S Y Chai Journal: Int J Biochem Cell Biol Date: 2003-06 Impact factor: 5.085
Authors: H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray Journal: Neurobiol Aging Date: 2000 May-Jun Impact factor: 4.673
Authors: Malcolm A Leissring; Wesley Farris; Alice Y Chang; Dominic M Walsh; Xining Wu; Xiaoyan Sun; Matthew P Frosch; Dennis J Selkoe Journal: Neuron Date: 2003-12-18 Impact factor: 17.173
Authors: Henning J Drews; Konstantin Yenkoyan; Ali Lourhmati; Marine Buadze; Daniela Kabisch; Stephan Verleysdonk; Stefan Petschak; Sandra Beer-Hammer; Tigran Davtyan; William H Frey; Christoph H Gleiter; Matthias Schwab; Lusine Danielyan Journal: Neurotherapeutics Date: 2019-07 Impact factor: 7.620
Authors: Sean Quinlan; Paula Merino-Serrais; Alessandra Di Grande; Heiko Dussmann; Jochen H M Prehn; Tríona Ní Chonghaile; David C Henshall; Eva M Jimenez-Mateos Journal: Front Immunol Date: 2019-07-24 Impact factor: 7.561